SLC6A6

Across TCGA pan-cancer cohorts, SLC6A6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC6A6 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SLC6A6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC6A6 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LSCC are the cancer types where SLC6A6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.006	19	view →
PDAC	OS	Quartile	All	0.542	0.783	.038	4	view →
LSCC	DFS	Quartile	II,III,IV	0.150	1.000	.038	3	view →
LUAD	DFS	Median	All	0.489	0.802	.011	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC6A6–CCRCC (DFS)

Open the CCRCC breakdown →